Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris.
about
Antiplatelet and anticoagulant therapy in elective percutaneous coronary interventionLow molecular weight heparins and glycoprotein IIb/IIIa antagonistsNew treatment guidelines for unstable angina/non-ST-segment elevation myocardial infartionNon-ST segment elevation acute coronary syndromes: treatment guidelines for the nurse practitionerCatheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatmentMacroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparinEnoxaparin in acute coronary syndromesShould glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No.Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome.Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.Low-molecular-weight heparins : mechanisms, trials, and role in contemporary interventional medicine.AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation.Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.Choice of agents to limit the coagulation cascade in acute coronary syndromes.Unfractionated versus fractionated heparin for percutaneous coronary intervention.Heparin dose during percutaneous coronary intervention: how low dare we go?Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction.Is the use of unfractionated heparin in acute coronary syndrome outmoded?Low-molecular-weight heparins in the cardiac catheterization laboratoryAnti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.Anticoagulation in pregnant women with prosthetic heart valves.Therapeutic strategies, immediate and mid-term outcomes in non-ST-segment elevation acute coronary syndromes with respect to age: a single-center registry of 488 consecutive patients.Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.Enoxaparin in clinical practice and clinical trials of non-ST-elevation Acute Coronary Syndrome (NSTE-ACS).Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals.Safety of enoxaparin versus unfractionated heparin during percutaneous coronary interventionEnoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction.2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and InterventiA novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study.Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study.Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions.Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy.Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention.Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study.Seamless anticoagulation therapy utilizing enoxaparin for acute coronary syndromes: Measure or not, here it comes!Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study).
P2860
Q24793199-F72CBFFF-3BDB-4F5F-93F4-E2EBDE635C16Q28193196-DA9C4608-A044-4CAF-8B79-017A42CD698CQ28194215-02DC9F41-433E-4E27-BA62-51E73AC03151Q28211708-8240BF5D-C73A-4514-A672-8EB8534B41BDQ28217792-59E5AFD5-E6AF-42F7-93A2-3EC538D19108Q28218235-0DE47B11-B319-42A2-9E31-4305A3A59673Q28301431-C47A5A31-1442-4F58-A7C8-1B8B9E723C02Q30312272-552BF0C4-C466-4F45-9F4E-6D98AF5596E6Q30402038-6E770FE7-AC51-46FB-83E5-9EFE1EDB10DCQ30438893-1A53BE61-7CE5-42D1-8506-9881E90FD6D7Q33360869-64FB3BC9-FBDB-4F42-ADEE-B9F7B933A442Q33378783-0EEB9789-7B94-460F-B170-EDF56146C2DEQ33378876-8105C3A4-EB0E-406E-8929-97C0645B50A6Q34445660-2CA5C4CE-9CF1-4820-9CE8-7C71763F8F26Q34674164-65406168-42D1-463E-AE29-945A703BC661Q34674179-0D894821-1974-4C94-9995-EC752AD3FE37Q34858594-18E1BE18-FEC9-4CA9-BE77-BCBB6E73E7FBQ35582491-C163C80D-CFA6-4BC3-B4D4-03DA3CB9136DQ35691998-C8888473-663A-4DA2-9605-276A885262B5Q35733959-E43C31F0-3D2F-4ADA-AEC9-E2A9C4FE9711Q35826954-0EE242F8-13F5-4182-99E8-08B46283A9B1Q35827649-E063B135-698D-4085-A540-72A9F405B7E6Q35862159-556B3A9E-C12E-40DE-A30F-9B9417312B5EQ35878091-7099782B-AAB0-49AB-9022-B4B8B7804CBCQ35944733-67910ECB-253D-43E2-B3F1-BDBBD19E7D59Q36211591-5B63765F-7CDB-4554-A308-B98FA396B793Q36634214-4C96C55B-ACD3-411E-8139-9E487B30F835Q37178035-D0125316-85F3-4584-8E5C-D2F1974E9134Q37445888-DA157745-38CF-4CE6-9CA1-48C36F888FDAQ37953885-81E61929-3159-49FF-96EB-C111C057BF9DQ39786426-AD0E1B87-FA89-4D06-ACD8-4ACC17743A11Q42607183-7A3A9A1C-EDAD-4DD1-9265-422B92FE99FEQ43078724-3EBAE3C5-C7EC-4298-AF68-C3DEC5B5A022Q44161856-42CC864E-3740-4D0D-B4B7-D879393A7F3EQ44601542-6F5599B0-DE2C-4EDC-A1F2-C8E2968FC313Q44706714-E579DB7C-456C-4622-9C9F-4C9F926B62A9Q44750904-D858D917-1C85-48F2-B697-E6F0DE4F6F35Q44750907-1734CA8E-147F-456F-9E5B-4D19A4A78EEFQ45029803-6246E01B-A9BD-4864-8831-9697E6B5081CQ46086107-724B4DF9-7993-4C87-9930-F23E64DB27B1
P2860
Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Percutaneous coronary interven ...... with unstable angina pectoris.
@ast
Percutaneous coronary interven ...... with unstable angina pectoris.
@en
type
label
Percutaneous coronary interven ...... with unstable angina pectoris.
@ast
Percutaneous coronary interven ...... with unstable angina pectoris.
@en
prefLabel
Percutaneous coronary interven ...... with unstable angina pectoris.
@ast
Percutaneous coronary interven ...... with unstable angina pectoris.
@en
P2093
P356
P1433
P1476
Percutaneous coronary interven ...... with unstable angina pectoris.
@en
P2093
P304
P356
10.1161/01.CIR.103.5.658
P407
P577
2001-02-01T00:00:00Z